Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering drug-responsive replication machinery for precise control of self-amplifying RNA.

Nature biomedical engineering·2026

Same author

Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.

Nature biomedical engineering·2026

Same author

Delivering base editors to the lungs.

Nature materials·2026

Same author

mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression.

Nature biotechnology·2026

Same author

Quantifying endosomal escape in vivo to guide lipid nanoparticle design.

Nature biotechnology·2026

Same author

Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia.

Nature biotechnology·2025

Search research articles

Related Experiment Video

Updated: Oct 13, 2025

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.

Chang Wang¹, Yuebao Zhang¹, Yizhou Dong^1,2

¹Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, United States.

Accounts of Chemical Research

|November 18, 2021

Summary

Lipid nanoparticles (LNPs) are advancing mRNA therapeutics for various diseases. Researchers are developing novel LNPs and engineering mRNA for improved delivery, efficiency, and therapeutic applications beyond COVID-19 vaccines.

More Related Videos

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Related Experiment Videos

Last Updated: Oct 13, 2025

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Area of Science:

Biotechnology and Pharmaceutical Sciences
Nanomedicine and Drug Delivery Systems
Molecular Biology and Genetic Engineering

Background:

Lipid nanoparticles (LNPs) have proven effective for mRNA delivery, notably in COVID-19 vaccines.
mRNA therapeutics show promise for protein replacement, genome editing, and cancer immunotherapy.
Challenges remain in developing efficient, low-toxicity delivery systems and optimizing mRNA for diverse cell types and therapeutic goals.

Purpose of the Study:

To summarize recent advances in designing and developing novel lipid-based delivery systems for mRNA therapeutics.
To highlight progress in engineering mRNA molecules for enhanced pharmaceutical properties and protein expression.
To showcase the application of integrated LNP and mRNA technologies in treating various diseases.

Main Methods:

Design and synthesis of novel ionizable lipid-like molecules, including benzene-core structures and biodegradable ester-containing lipids.
Development of biomimetic lipids such as vitamin-derived, chemotherapeutic-conjugated, phospholipids, and glycolipids.
Optimization of mRNA chemistry through modified nucleotides (e.g., pseudouridine) and engineering of 5' and 3' untranslated regions (UTRs).

Main Results:

Identification of a lead ionizable lipid-like compound (TT3) for effective in vitro and in vivo mRNA delivery.
Demonstrated enhancement of protein expression through mRNA chemical modifications and UTR engineering.
Successful application of LNP-mRNA formulations in preclinical models for hemophilia, infectious diseases, and cancer immunotherapy.

Conclusions:

Lipid-mRNA nanoparticle formulations are crucial for public health, as evidenced by their role in the COVID-19 pandemic.
Continued integration of chemistry, engineering, materials science, pharmaceutical sciences, and medicine is vital for clinical translation.
Further development promises broader clinical applications of LNP-mRNA technology for diverse human health benefits.